Potential new therapies for the treatment of HIV-1 infection

被引：33

作者：

Condra, JH ^{[1
]}

Miller, MD ^{[1
]}

Hazuda, DJ ^{[1
]}

Emini, EA ^{[1
]}

机构：

[1] Merck Res Labs, West Point, PA 19486 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2002年 / 53卷

关键词：

protease; reverse transcriptase; integrase; entry inhibitors; assembly inhibitors;

D O I：

10.1146/annurev.med.53.082901.104110

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The development and clinical use of chemotherapeutic agents for the treatment of persistent HIV-1 infection over the past decade has profoundly and favorably affected the course of HIV-1 disease for many infected individuals. Unfortunately, the long-term use of these therapies is complicated by unwanted metabolic side effects, by issues of adherence, and by the selection of viral variants with reduced susceptibility. These complications have spurred the search for new anti-HIV-1 agents having improved pharmacological properties and expressing activity against viral variants resistant to the currently available agents. This brief review describes the current state of this search as well as potentially novel viral targets for chemotherapeutic intervention.

引用

收藏

页码：541 / 555

页数：15

相关论文

共 76 条

[1] EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES [J].

ALLAWAY, GP ;

DAVISBRUNO, KL ;

BEAUDRY, GA ;

GARCIA, EB ;

WONG, EL ;

RYDER, AM ;

HASEL, KW ;

GAUDUIN, MC ;

KOUP, RA ;

MCDOUGAL, JS ;

MADDON, PJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (05) :533-539

[2] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[3] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors [J].

Back, NKT ;

van Wijk, A ;

Remmerswaal, D ;

van Monfort, M ;

Nijhuis, M ;

Schuurman, R ;

Boucher, CAB .

AIDS, 2000, 14 (01) :101-102

[4] Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].

Berger, EA ;

Murphy, PM ;

Farber, JM .

ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700

[5]

BORROTOESODA K, 1999, 39 INT C ANT AG CHEM, P316

[6]

BROWN PO, 1998, RETROVIRUSES, P161

[7] STRUCTURE OF INFLUENZA HEMAGGLUTININ AT THE PH OF MEMBRANE-FUSION [J].

BULLOUGH, PA ;

HUGHSON, FM ;

SKEHEL, JJ ;

WILEY, DC .

NATURE, 1994, 371 (6492) :37-43

[8] A quantitative assay for HIV DNA integration in vivo [J].

Butler, SL ;

Hansen, MST ;

Bushman, FD .

NATURE MEDICINE, 2001, 7 (05) :631-634

[9] Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41 [J].

Caffrey, M ;

Cai, ML ;

Kaufman, J ;

Stahl, SJ ;

Wingfield, PT ;

Covell, DG ;

Gronenborn, AM ;

Clore, GM .

EMBO JOURNAL, 1998, 17 (16) :4572-4584

[10] Influenza hemagglutinin is spring-loaded by a metastable native conformation [J].

Carr, CM ;

Chaudhry, C ;

Kim, PS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14306-14313

← 1 2 3 4 5 6 7 8 →